Increased levels of interleukin-6 (IL-6) in serum and spontaneous in vitro production of IL-6 by lymph node mononuclear cells of patients with angio-immunoblastic lymphadenopathy with dysproteinemia (AILD), and clinical effectiveness of cyclosporin A

Leukemia

Volumn 10, Issue 9, 1996, Pages 1504-1508

  Yamamura, M ^a   Honda, M ^a   Yamada, Y ^b   Itoyama, T ^a   Sohda, H ^a   Yubashi, T ^a   Momita, S ^a   Kamihira, S ^b   Ohmoto, Y ^c   Tomonaga, M ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Angio immunoblastic lymphadenopathy with dysproteinemia (AILD); Cyclosporin A (CSA); Cytokines; Immunosuppressive therapy; Interleukin 6 (IL 6)

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CYCLOSPORIN A; GAMMA INTERFERON; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ARTICLE; BLOOD LEVEL; CASE REPORT; DRUG EFFICACY; DYSPROTEINEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE; MALE; MONONUCLEAR CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; T CELL LYMPHOMA;

EID: 9544230673     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Mandler RN, Kerrigan DP, Smart J, Kuis W, Villiger P, Lotz M. Castleman's disease in POEMS syndrome with elevated interleukin-6. Cancer 1992; 69: 2697-2703.
2. Hsu S-M, Waldron JA, Xie SS, Barlogie B. Expression of interleukin-6 in Castleman's disease. Hum Pathol 1993; 24: 833-839.
3. Beck JT, Hsu S-M, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal antiinterleukin-6 antibody. New Engl J Med 1994; 330: 602-605.
4. Gherardi RK, Belec L, Fromont G, Divine M, Malapert D, Gaulard P, Degos J-D. Elevated levels of interleukin-1β (IL-1β) and IL-6 in serum and increased production of IL-1β mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome. Blood 1994; 83: 2587-2593.
5. Yee C, Sutcliffe S, Messner HA, Minden MD. Interleukin-6 levels in the plasma of patients with lymphoma. Leuk Lymphoma 1992; 7: 123-129.
6. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res 1993; 53: 2118-2122.
7. Stasi R, Zinzani PL, Galieni P, Lauta VM, Damasio E, Dispensa E, Dammacco F, Papa G, Tura S. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br J Haematol 1994; 88: 770-777.
8. Seymour JF, Talpaz M, Cabanillas F, Welzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995; 13: 575-582.
9. Tienhaara A, Pulkki K, Mattila K, Irjala K, Pelliniemi T-T. Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis. Br J Haematol 1994; 86: 391-393.
10. Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinemia. Lancet 1974; 1: 1070-1073.
11. Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy. Diagnosis and clinical course. Am J Med 1975; 59: 803-818.
12. Lukes RJ, Tindle BH. Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin's disease. New Engl J Med 1975; 292: 1-8.
13. Hsu S-M, Waldron JA Jr, Fink L, King C, Xie S-S, Mansouri A, Barlogie B. Pathogenic significance of interleukin-6 in angioimmunoblastic lymphadenopathy-type T-cell lymphoma. Hum Pathol 1993; 24: 126-131.
14. Frizzera G, Kaneko Y, Sakurai M. Angioimmunoblastic lymphadenopathy and related disorders: a retrospective look in search of definitions. Leukemia 1989; 3: 1-5.
15. Weiss LM, Strickler JG, Dorfman RF, Horning SJ, Warnke RA, Sklar J. Clonal T-cell populations in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Am J Pathol 1986; 122: 392-397.
16. Knecht H, Odermatt BF, Hayoz D, Kuhn L, Bachmann F. Polyclonal rearrangements of the T-cell receptor β-chain in fatal angioimmunoblastic lymphadenopathy. Br J Haematol 1989; 73: 491-496.
17. Honda M, Smith HR, Steinberg AD. Studies of the pathogenesis of angioimmunoblastic lymphadenopathy. J Clin Invest 1985; 76: 332-340.
18. Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1-10.
19. Wolvekamp MCJ, Marquet RL. Interleukin-6: historical background, genetics and biological significance. Immunol Lett 1990; 24: 1-9.
20. Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, Kishimoto T. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988; 167: 332-344.
21. Bertolini JN, Benson EM. The role of human interleukin-6 in B-cell isotype regulation and differentiation. Cell Immunol 1990; 125: 197-209.
22. Splawski JB, McAnally LM, Lipsky PE. IL-2 dependence of the production of human B cell differentiation by IL-6 (BSF-2). J Immunol 1990; 144: 562-569.
23. Hansen MB, Svenson M, Diamant M, Abell K, Bendtzen K. Interleukin-6 autoantibodies: possible biological and clinical significance. Leukemia 1995; 9: 1113-1115.
24. Motro B, Itin A, Sachs L, Keshet E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Prac Natl Acad Sci USA 1990; 87: 3092-3096.
25. Pangalis GA, Moran EM, Nathwani BN, Zelman RJ, Kim H. Rappaport H. Angioimmunoblastic lymphadenopathy. Long-term follow-up study. Cancer 1983; 52: 318-321.
26. Ganesan TS, Dhaliwal HS, Dorreen MS, Stansfeld AG, Habeshaw JA, Lister TA. Angio-immunoblastic lymphadenopathy: a clinical, immunological and molecular study. Br J Cancer 1987; 55: 437-442.
27. Steinberg AD, Seldin MF, Jaffe ES, Smith HR, Klinman DM, Krieg AM, Cossman J. Angioimmunoblastic lymphadenopathy with dysproteinemia. Ann Intern Med 1988; 108: 575-584.
28. Siegert W, Nerl C, Meuthen I, Zahn T, Brack N, Lennert K, Huhn D. Recombinant human interferon-α in the treatment of angioimmunoblastic lymphadenopathy: results in 12 patients. Leukemia 1991; 5: 892-895.
29. Murayama T, Imoto S, Takahashi T, Ito M, Matozaki S, Nakagawa T. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with cyclosporin A. Cancer 1992; 69: 2567-2570.
30. Borel JF. Mechanism of action and rationale for cyclosporin A in psoriasis. Br J Dermatol 1990; 122: 5-12.
31. Emilie D, Wijdenes J, Gisselbrecht C, Jarrousse B, Billaud E, Blay J-Y, Gabarre J, Gaillard J-P, Brochier J, Raphael M, Boue F, Galanaud P. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect of lymphoma growth and on B clinical symptoms. Blood 1994; 84: 2472-2479.
32. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-636.
33. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12; 1179-1186.
34. Weber J, Yang JC, Tapalian SL, Parkinson DR, Schwartzentruber DS, Ettinghausen SE, Gunn H, Mixon A, Kim H, Cole D, Levin R, Rosenberg SA. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 1993; 11: 499-506.